Lindsay A. Zilliox, MD

Education

• Miami University, Oxford, Ohio. B.A., Zoology, Cum laude, 1996-2000
• The Ohio State University College of Medicine, M.D., 2000-2004
• University of Maryland, Baltimore. M.S., Clinical Research, 2011-2015

Post Graduate Education and Training

• University of Maryland Medical Center and Baltimore VA Medical Center, Department of Internal Medicine Internship, 2004-2005
• University of Maryland Medical Center and Baltimore VA Medical Center, Department of Neurology Residency Program, 2005-2008
• University of Maryland Medical Center, Department of Neurology, Neuromuscular Division Fellowship in Clinical Neurophysiology, 2008-2009

Dr. Lindsay Zilliox is an Associate Professor in the Department of Neurology and Director of the Neuromuscular Division at the University of Maryland School of Medicine. She graduated from The Ohio State University College of Medicine and completed her neurology residency and fellowship in clinical neurophysiology at the University of Maryland Medical Center and the Baltimore VA Medical Center.  She is board certified in Neurology and Clinical Neurophysiology as well as Autonomic Disorders and holds a masters degree in Clinical Research from the University of Maryland.

Dr. Zilliox has clinical research interests in peripheral neuropathies and specifically in lifestyle interventions in the treatment of neuropathy in diabetes and prediabetes as well as the metabolic syndrome. In addition, she performs nerve conduction studies and electromyography as well as autonomic nervous system testing.

neuropathy, diabetic neuropathy, clinical neurophysiology, electromyography, autonomic nervous system testing

HEALY ALS Platform Trial; HEALEY ALS Platform Trial Study Group. Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2025 Jun;24(6):500-511. PMID 40409314

Zilliox LA, Russell JW. Is there cardiac autonomic neuropathy in prediabetes? Auton Neurosci. 2020 Dec;229:102722. PMID:33011523

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illia I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017 Dec;16(12):976-986. PMID 29066163

Zilliox LA, Chadrasekaram K, Kwan JY, Russell JW. Diabetes and Cognitive Impairment. Curr Diab Rep. 2016;16(9):87. PMID: 27491830

Zilliox LA, Ruby SK, Singh S, Zhan M, Russell JW. Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. J Diabetes Complications. 2015;29(3):372-7. PMID: 25690405

Russell JW, Zilliox LA. Diabetic neuropathies. Continuum. 2014;20(5):1226-40. PMID 25299279.

Zilliox L, Peltier AC, Wren PA, Anderson A, Smith AG, Singleton JR, Feldman EL, Alexander NB, Russell JW. Assessing autonomic dysfunction in early diabetic neuropathy: the Survey of Autonomic Symptoms. Neurology. 2011;76(12):1099-105. PMID: 2142246